Abstract
FOOD AND DRUG Administration (FDA) officials classify thalidomide as an orphan drug, one of 133 such pharmaceuticals currently being studied in the treatment of 96 relatively rare diseases (<i>JAMA</i>. 1990;263:793). Two such studies of thalidomide are under way. In lepromatous leprosy, it has been the drug of choice since 1966 in treating erythema nodosum leprosum and now is in phase III (extensive clinical trials in humans) developmental status. In graft-versus-host disease, the most common cause of death following bone marrow transplantation, it has been in clinical trials since 1987 and is in phase II (effectiveness testing in humans) developmental status. (Please see accompanying article.) In the United States, thalidomide is obtained under investigational new drug status from two sources. The National Hansen's Disease Center, Carville, La, which is conducting the leprosy study, obtains reagent-grade thalidomide from Andrulis Research Corporation, Bethesda, Md. Andrulis manufactures the drug under contract with the US
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
